FOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval

Stock News12-09 20:15

FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively referred to as "Henlius") recently received approval from the National Medical Products Administration (NMPA) to conduct the following clinical trials in China for HLX22 (a recombinant humanized anti-HER2 monoclonal antibody injection) combined with HLX87 injection (a HER2-targeted antibody-drug conjugate): (1) Phase II/III clinical trials for first-line treatment of HER2-positive breast cancer (BC); (2) Phase II/III clinical trials for HER2-positive breast cancer neoadjuvant therapy (BC neo). Henlius plans to initiate the relevant clinical studies in China once conditions are met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121382172?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121382172","market":"other","top_or_hot":-1,"title":"FOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration (NMPA) to conduct the following clinical trials in China for HLX22 (a recombinant humanized anti-HER2 monoclonal antibody injection) combined with HLX87 injection (a HER2-targeted antibody-drug conjugate): (1) Phase II/III clinical trials for first-line treatment of HER2-positive breast cancer (BC); (2) Phase II/III clinical trials for HER2-positive breast cancer neoadjuvant therapy (BC neo). Henlius plans to initiate the relevant clinical studies in China once conditions are met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration (NMPA) to conduct the following clinical trials in China for HLX22 (a recombinant humanized anti-HER2 monoclonal antibody injection) combined with HLX87 injection (a HER2-targeted antibody-drug conjugate): (1) Phase II/III clinical trials for first-line treatment of HER2-positive breast cancer (BC); (2) Phase II/III clinical trials for HER2-positive breast cancer neoadjuvant therapy (BC neo). Henlius plans to initiate the relevant clinical studies in China once conditions are met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0096","symbol_name":"民营医院","start_time":0,"source_url":"","article_id":"1121382172","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121382172","pubTimestamp":1765282519,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively referred to as \"Henlius\") recently received approval from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0096":"民营医院","BK1191":"制药","BK0196":"行业龙头","BK1515":"抗疫概念","BK0012":"证金概念","BK0060":"抗癌","BK0188":"融资融券","BK0187":"一线龙头","BK0175":"白马股","BK1593":"医美概念股","02196":"复星医药","BK0239":"医药制造","BK0028":"国家队","BK0183":"MSCI概念"},"translate_title":"复星医药（600196.SH）：HLX22联合HLX87注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively referred to as \"Henlius\") recently received approval from the National Medical Products Administration (NMPA) to conduct the following clinical trials in China for HLX22 (a recombinant humanized anti-HER2 monoclonal antibody injection) combined with HLX87 injection (a HER2-targeted antibody-drug conjugate): (1) Phase II/III clinical trials for first-line treatment of HER2-positive breast cancer (BC); (2) Phase II/III clinical trials for HER2-positive breast cancer neoadjuvant therapy (BC neo). Henlius plans to initiate the relevant clinical studies in China once conditions are met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121382172","isCrawlerRequest":true}